LG Chem Licenses Asimov AI Platform for Biologics
The pharmaceutical company is integrating AI-driven genetic design to accelerate its biologics cell line development.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you believe the integration of AI into pharmaceutical research will lead to better medical treatments?
LG Chem has licensed the CHO Edge System from the Boston-based biotechnology company Asimov to advance its biologics cell line development. This deal incorporates Asimov's AI-driven genetic design software and proprietary transposase technology into the pharmaceutical company's development pipeline.
Why it matters
The adoption of AI-driven design platforms reflects a broader industry shift toward managing the complexity of next-generation therapeutics like multispecific antibodies and antibody-drug conjugates. By streamlining cell line engineering, developers aim to expand the therapeutic design space for these advanced biologics.
The CHO Edge System, which LG Chem has integrated, uses AI-driven genetic design software to automate and optimize the creation of cell lines used to manufacture therapeutic proteins.
The players
LG Chem
A major corporation with a diverse portfolio spanning petrochemicals, advanced materials, and life sciences.
Asimov
A Boston-based biotechnology company specializing in AI-driven genetic design for therapeutic development.
The details
The platform includes the Kernel AI-driven genetic design software and the Chrysalis transposase, an enzyme that facilitates the movement of genetic material within the genome. These components work together to optimize the cellular machinery required to produce complex biologics, such as fusion proteins and multispecific antibodies, which are proteins engineered to bind to multiple distinct antigens. By integrating this platform, LG Chem aims to improve the efficiency of identifying high-performing cell lines for drug production.
Timeline
October 21, 2026: Asimov announced the licensing agreement with LG Chem.
The Tech Race
Asimov's CHO Edge System enters a competitive field of synthetic biology platforms aimed at digitizing drug discovery. This partnership places the platform in the hands of a global life sciences entity as the race to reliably manufacture multispecific antibodies intensifies.
This agreement integrates new design tools into LG Chem’s existing biologics development workflows immediately. Future drug candidates utilizing this platform are expected to benefit from faster cell line engineering, though the timeline for specific clinical trials remains at the company's discretion.
The takeaway
The move underscores the growing reliance on AI-driven genetic architecture to navigate the production of complex biologics. Observers should track whether the integration of these systems correlates with shortened timelines for candidate selection in LG Chem's upcoming life sciences pipeline.
Further reading
For more on the latest research and developments in this field, see Biotech.
Live Poll
Do you believe the integration of AI into pharmaceutical research will lead to better medical treatments?
